Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Combinations as First-Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2023-503418-63-00Phase 2Completed
- Sponsor
- BeOne Medicines
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by BeOne Medicines. Primary endpoint: Confirmed Objective Response Rate (ORR). Started Oct 2023; status: completed.
02
Drugs
tislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-503418-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503418-63-00.